call Toll Free (US/Canada) : +1 866 658 6826 | call +1 425 320 4776 | call (UK) : +44 1865 60 0662 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Home Blog LEO Pharma and PellePharma has entered into partnership to develop therapies for rare skin diseases

LEO Pharma and PellePharma has entered into partnership to develop therapies for rare skin diseases

  • Published | 22 November 2018
LEO Pharma and PellePharma collaborated with USD 760 Million to innovate advance therapies for are skin diseases
India: LEO Pharma obtains the minority stake in PellePharm and offers additional non-dilutive capital to fund PellePharm development programs, it obtains an option to acquire all shares in PellePharm. A strategic development and commercialized collaboration were made between the two companies to address unmet medical needs of various skin diseases, develop advancing innovation and access potential therapies for patients with life-altering conditions, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinoma (BCC), two distinct and rare forms of skin cancer. Under this agreement, LEO Pharma has initially committed USD 70 million consists of equity financing and financial R&D support to fund the global Phase 3 trial for the patidegib topical gel for the prevention and treatment of Gorlin Syndrome. PellePharm and its stockholders could receive up to an additional USD 690 million including merger consideration, and regulatory and commercial milestone payments. The agreement establishes a joint development committee with PellePharm maintaining responsibility for global development and LEO Pharma supporting in an advising role. Both companies will jointly drive commercialization planning, and Anders Kronborg, a chief financial officer of LEO Pharma, will join PellePharm’s board of directors According to BlueWeave Consulting, spending in the purchase of medicine is anticipated to increase at significantly by 2018-22 which is estimated to be worth USD 26-30 billion in India, accelerated by rapid urbanization, growing consumer spending and increasing healthcare insurance. Further better growth in domestic sales will also enhance the ability of companies to expand their product portfolio focusing chronic therapies for diseases such as such as anti-diabetes, cardiovascular, anti-cancer and anti-depressants that are on the rise. Several governments are reducing the costs of healthcare expenses offering better healthcare facilities to minors. In addition, the government initiative to implement rural health programmes, preventive vaccines and lifesaving drugs at reasonable price too low-income group people will accelerate growth in the pharmaceutical market. According to upcoming report by BlueWeave Consulting on “Global Medicine Market, By Type, By Application, By Region- Industry Analysis, Size, Share, Growth, Trends & forecast by 2018-2025”, globally, the medicine market is growing phenomenally among the population due to the rise in personal healthcare devices and integration of smart technologies in the healthcare system. Moreover, increasing collaborations and corporations between various ecosystem players are aiding in the robust growth of the precision medicine market which will augment market growth.